


CLAIMS

1. A compound having the Formula I



Formula I

5

a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug with the proviso that [5-cyclopropyl-1-(quinolin-5-yl)-1H-pyrazole-4-carbonyl]guanidine is not included.

- 10 2. [5-Cyclopropyl-1-(2-quinolon-5-yl)-1H-pyrazole-4-carbonyl]guanidine, or a pharmaceutically acceptable salt thereof.
3. A method of reducing tissue damage resulting from ischemia or hypoxia comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1, a prodrug thereof or a pharmaceutically
- 15 acceptable salt of said compound or of said prodrug.
4. A method as recited in claim 3 wherein the tissue is cardiac, brain, liver, kidney, lung, gut, skeletal muscle, spleen, pancreas, nerve, spinal cord, retina tissue, the vasculature, or intestinal tissue.
5. A method as recited in claim 3 wherein the amount of the compound of
- 20 claim 1, a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug is about 0.01 mg/kg/day to about 50 mg/kg/day.
6. A method as recited in claim 5 wherein the mammal is a female or male human.

7. A method as recited in claim 6 wherein said tissue is heart tissue.
8. A method as recited in claim 6 wherein said tissue is brain tissue.
9. A method as recited in claim 6 wherein said tissue is liver tissue.
10. A method as recited in claim 6 wherein said tissue is kidney tissue.
- 5 11. A method as recited in claim 6 wherein said tissue is lung tissue.
12. A method as recited in claim 6 wherein said tissue is gut tissue.
13. A method as recited in claim 6 wherein said tissue is skeletal muscle tissue.
14. A method as recited in claim 6 wherein said tissue is spleen tissue.
15. A method as recited in claim 6 wherein said tissue is pancreas tissue.
- 10 16. A method as recited in claim 6 wherein said tissue is retina tissue.
17. A method as recited in claim 6 wherein the compound is administered prophylactically.
18. A method as recited in claim 6 wherein the compound is administered prior to surgery.
- 15 19. A method as recited in claim 6 wherein the compound is administered prior to cardiac surgery.
20. A method as recited in claim 6 wherein the compound is administered during surgery.
21. A method as recited in claim 6 wherein the compound is administered during cardiac surgery.
- 20 22. A method as recited in claim 6 wherein the compound is administered within twenty-four hours after surgery.
23. A method as recited in claim 6 wherein the compound is administered within twenty four hours after cardiac surgery.
- 25 24. A method as recited in claim 6 wherein the tissue damage resulting from ischemia is ischemic damage and is incurred during organ transplantation.
25. A method as recited in claim 6 wherein the compound is administered to prevent perioperative myocardial ischemic injury.
26. A pharmaceutical composition which comprises an amount of the
- 30 compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent.
27. A pharmaceutical composition for the reduction of tissue damage resulting from ischemia or hypoxia which comprises a therapeutically effective amount of the

28. A method as recited in claim 6 wherein the compound is administered prior to, during and after surgery.

30. A method of producing [5-cyclopropyl-1-(2-quinolon-5-yl)-1H-pyrazole-4-carbonyl]guanidine by administering [5-cyclopropyl-1-(quinolin-5-yl)-1H-pyrazole-4-carbonyl]guanidine to a human.

31. Substantially pure [5-cyclopropyl-1-(2-quinolon-5-yl)-1*H*-pyrazole-4-carbonyl]guanidine, or a pharmaceutically acceptable salt of said compound.